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The first literary reference to persistent pulmonary hypertension 
(PH) of the newborn (PPHN) can be found in 1969 by Gersony et 
al.,[1,2] who described it as persistence of physiologic characteristics of 
the fetal circulation in the absence of disease. Defined as a failure of 
normal circulatory transition at birth, or more specifically as failure 
of the pulmonary vasculature to relax after birth, with continued 
shunting of non-oxygenated blood into the systemic circulation 
via fetal channels (ductus arteriosus and foramen ovale), it remains 
a challenging neonatal emergency to manage.[3-6] Term and near-
term infants are most commonly affected, but PPHN can occur in 
premature infants.[4] 
The incidence of PPHN in developed countries has been estimated 
as 1.9 per 1 000 live births; however, the incidence is likely to be 
higher in developing countries.[2,3,5,7] PPHN constitutes ~10% of 
neonatal intensive care unit (NICU) admissions, with the reported 
mortality rate ranging from 10 to 20%.[4,5,8-10]
Physiology 
The normal physiological state of a fetus is best described as 
hypoxaemic, with PH and reduced pulmonary blood flow, and with the 
placenta responsible for gas and nutrient exchange.[3,4,6,10] It is important 
to understand that the fetus is not hypoxic, as adequate oxygen delivery 
to the tissues is maintained and facilitated by a high cardiac output and 
high fetal haemoglobin levels with increased oxygen affinity.[3]
Factors involved in maintaining an increased pulmonary vascular 
resistance (PVR) in utero include fluid-filled lungs, decreased nitric 
oxide (NO) and prostacyclin (PGI2), and increased endothelin-1 
(ET-1).[4] Products of the prostaglandin pathway, such as thromboxane 
and leukotriene, also play a role. Serotonin increases fetal PVR, which 
brings into question the safety of using selective serotonin reuptake 
inhibitors (SSRIs) during pregnancy.[3,4,6,11]
Fetal circulation
The systemic and pulmonary circulations of the fetus function in 
parallel, where both ventricles essentially eject blood into the aorta 
and use the foramen ovale and ductus arteriosus to bypass the 
pulmonary circulation. Only 13 - 25% of blood ejected will reach 
pulmonary circulation.[3,4,6,11]
Transition to extrauterine life
The normal transition from ‘parallel’ to ‘series’ circulation starts 
with a rapid decrease in PVR with the first breath, and an increase in 
systemic vascular resistance with the removal of the low-resistance 
placenta after umbilical cord clamping.[3,10] The first breath fills the 
lungs with air, causing an eight-fold increase in pulmonary blood 
flow. The resulting shear stress and oxygenation up-regulates the 
expression of endothelial NO synthase (eNOS).[3,4,6] Endothelial NO 
synthesised from l-arginine activates soluble guanylyl cyclase (sGC), 
converting cyclic guanosine triphosphate (cGTP) to cyclic guanosine 
monophosphate (cGMP), which facilitates smooth muscle relaxation.[4-6] 
Oxygenation also inhibits phosphodiesterase-5 (PDE5), increasing 
the availability of cGMP.[4]
The production of prostaglandin endoperoxides from arachadonic 
acid in the endothelium, specifically PGI2, stimulates adenylyl 
cyclase to convert adenosine triphosphate (ATP) to cyclic adenosine 
monophosphate (cAMP), which also facilitates pulmonary vaso-
dilatation.[4,6] Phosphodiesterase-3 (PDE3) increases the availability of 
cAMP. Prostaglandins decrease PVR less than does NO.[4]
Aetiology and pathophysiology
When there is failure of the normal transition to extra-uterine life, 
with the persistence of increased PVR, PPHN occurs. Hypoxia, 
acidosis and hypercarbia cause vasoconstriction, and play an 
important role in the underlying pathogenesis.[10]
The causes of PPHN can be classified into four groups: 
underdevelopment, maldevelopment, maladaptation and intrinsic 
obstruction (Table 1).[3,4,6]
Meconium aspiration syndrome (MAS) is the most common 
cause of PPHN.[4,6] Meconium-stained liquor occurs in 5 - 24% of 
normal pregnancies, and of these 5% will develop MAS. Meconium 
causes airway obstruction, inactivation of surfactant and chemical 
pneumonitis, owing to the release of proinflammatory cytokines. The 
resultant decreased ventilation/perfusion ratio, with hypoxaemia and 
hypercarbia, may lead to PPHN.[3]
Idiopathic or ‘black-lung’ PPHN occurs in 20 - 25% of cases, with 
‘black lung’ referring to the paucity of pulmonary vascularity.[3,4,6,8] 
There is an absence of parenchymal lung disease, as the underlying 
problem is vascular smooth muscle hyperplasia of the normally 
muscle-free arteries. A questionable association with antenatal use of 
non-steroidal anti-inflammatory drugs and SSRIs exists.[12]
Congenital diaphragmatic hernia is associated with lung hypoplasia 
and the decreased cross-sectional area of the pulmonary vascular 
bed. Lung damage is often exacerbated by volutrauma, hyperoxia and 
mechanical ventilation.[6] 
Persistent pulmonary hypertension of the newborn is a neonatal emergency with a high mortality rate in spite of several advances in the 
management thereof. The underlying pathophysiology is complex and multifactorial. The gold standard of treatment is inhaled nitric 
oxide, yet up to a third of patients will not respond to standard treatment. This article reviews treatment modalities available, as well as the 
evidence to support the use of these treatment options.
S Afr J Child Health 2016;10(4):194-198. DOI:10.7196/SAJCH.2016.v10i4.1145
The management of persistent pulmonary 
hypertension of the newborn: A review
L G Lloyd, MB ChB, DCH (SA), FC Paed (SA), MMed (Paed), Cert Neonatology (SA);  
J Smith, MB ChB, MMed, FC Paed (SA), PhD (Paed)
Division of Neonatology, Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Children’s Hospital, Cape Town, 
South Africa
Corresponding author: L G Lloyd (lgl@sun.ac.za)
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
195        SAJCH     DECEMBER 2016    Vol. 10    No. 4
REVIEW
PH can occur in premature infants, with one-third of patients with 
bronchopulmonary dysplasia (BPD) having an underlying diagnosis 
of PH. The combination of BPD and PH is associated with a poor 
outcome.[3,6,8]
Congenital cardiac disease, such as total anomalous pulmonary 
venous return and hypoplastic left heart syndrome, may also present 
with PPHN.[4] 
Risk factors
Several risk factors have been identified, including an unfavourable 
perinatal fetal environment which, in combination with certain 
epigenetic factors, may play a role in the expression of genes involved 
in the regulation of perinatal pulmonary circulation (Table 2).[2]
Diagnosis
PPHN presents in the first 24 hours of life. The classic clinical 
presentation includes respiratory distress, cyanosis, hypoxaemia and 
acidosis.[5] The echocardiogram is the gold standard for the diagnosis 
of PPHN (Table 3).[3-5,9]
Although the echocardiogram is the gold standard for the 
diagnosis of PPHN, it is often not available in resource-limited 
settings, therefore other special investigations are of critical 
importance (Table 4).[13] The traditional comprehensive structural 
and functional echocardiogram performed by cardiologists can 
be supplemented by training neonatologists to perform a targeted 
neonatal echocardiogram (TnEcho) to expedite diagnosis of PPHN 
and to monitor the response to therapy.[14]
Severity of PPHN
The severity of PPHN can be calculated using the oxygenation index 
(Table 5).[3]
Table 2. Risk factors for the development of PPHN[4-6]
Maternal factors
African or Asian maternal race
Preconceptual maternal obesity (BMI >27)
Maternal chronic diseases, e.g. diabetes, asthma
Use of SSRIs, e.g. fluoxetine, after 20 weeks’ gestation




Meconium-stained liquor and meconium aspiration syndrome




Large for gestational age




BMI = body mass index; SSRI = seletive serotonin uptake inhibitors.
Table 3. Echocardiographic diagnosis of PPHN[3-5,9,10]
Exclude underlying cardiac 
abnormalities
To assist therapeutic decision-
making
TR jet velocity To calculate RV pressure with 
modified Bernoulli equation
Direction of ductal shunting Identify right-to-left shunting 
Alignment of the interventricular 
septum
Rough indication of pulmonary 
blood pressure
Rounded: PAP <50% of systemic 
pressure
Flattened: PAP is 50 - 100% of 
systemic pressure
Bows into the left ventricle: PAP 
exceeds systemic pressure
TR = tricuspid regurgitation; RV= right ventricle; PAP = pulmonary artery pressure.






5 - 10% higher than 
post-ductal
Labile hypoxaemia[3] Marked change in 
oxygen saturation with 





correlating with the 
amount of parenchymal 
disease seen on CXR
CXR[4,10] Identify underlying parenchymal disease
Complete blood 
count[4]
Diagnose infection and/or polycythaemia
Serum glucose  
and calcium[4]
Underlying metabolic causes
BNP[3-6] Correlates with TR jet
Monitor response to treatment
Not routinely used
CXR = chest X-ray; BNP = brain natriuretic peptide.
Table 1. Pathophysiology of PPHN[3,4,6]
Underdevelopment Maldevelopment Maladaptation Intrinsic obstruction
Pathology Decreased vascular growth Abnormal vascular structure Normal vasculature with 
hypoxia induced vasospasm
High viscosity resulting in 




















CDH = congenital diaphragmatic hernia; MAS = meconium aspiration syndrome; RDS = respiratory distress syndrome; IDM = infant of a diabetic mother.




The first-line management includes ventilation, oxygenation, main-
taining systemic blood pressure and maintaining homeostasis.[10] 
Stabilisation, establishing venous access and treating the underlying 
cause are critically important. 
Supportive care
Hypothermia, acidosis, polycythaemia, hypoglycaemia, hypocal-
caemia and hypomagnesaemia should be corrected appro-priately.[3,10] 
Correction of acidosis with controlled alkalosis using an alkali infusion 
and hyperventilation is no longer advocated due to the association with 
sensorineural hearing loss and impaired cerebral perfusion.[3,10] 
Minimal handling and judicious sedation is advised to avoid labile 
hypoxaemia. Antimicrobial therapy should be initiated if underlying 
infection is suspected.[6]
Mechanical ventilation and oxygenation
Oxygen is a pulmonary vasodilator; however, hyperoxia and ventilation 
with 100% oxygen has been associated with a reduced response to NO in 
experimental lamb models.[3,4] The aim of mechanical ventilation should 
be to maintain a PaCO2 of 40 - 60 mmHg (5.3 – 8.0 kPa) and PaO2 of 
60 – 90 mmHg (8 - 12 kPa) by using gentle ventilation to optimise 
lung volume.[4,5] High-frequency oscillatory ventilation (HFOV) can 
minimise lung injury, but has not been proven to have a clear benefit over 
conventional ventilation, except when used in combination with inhaled 
NO (iNO) in the treatment of MAS.[4,5,15] HFOV is recommended if peak 
inspiratory pressures (PIP) of >28 cmH2O or tidal volumes > 6 mL/kg are 
required to maintain PaCO2 <60 mmHg (<8 kPa).[3] 
Surfactant 
In patients with MAS or pneumonia, surfactant may reduce 
the need for extracorporeal membrane oxygenation (ECMO), 
but does not reduce the duration of ventilation, length of the 
hospital stay or incidence of complications.[4,5] Prior to giving 
the surfactant, adequate recruitment of lung volume should be 
prioritised. [4,5] The greatest benefit was seen when administered at 
an OI of 15 - 25.[3,6] Dosages of 50 – 200 mg/kg may be used up to 
four times in the first 24 hours.[16] The use of a surfactant in CDH 
is not recommended, unless there is clear evidence of surfactant 
deficiency, and then only 50% of the dose should be given because 
of the underlying pulmonary hypoplasia.[3]
Management of systemic hypotension 
Systemic hypotension should be managed with fluids, vasopressors 
and inotropes. The optimal blood pressure (BP) has not been 
determined in a randomised controlled trial (RCT), and should 
therefore be maintained at the normal value for the gestational age.[5,6] 
Supraphysiologic BP ought to be avoided, as it may add to ventricular 
strain and increase endothelial dysfunction by increasing shear stress 
in the constricted pulmonary circuit.[3] 
Inotropic support should be considered early, as decreased 
systemic BP exacerbates right-to-left shunting and worsens hypox-
aemia.[3,10] Dopamine is commonly used, but at doses >10  µg/kg/
min it is not selective to systemic vasculature and may increase the 
PVR.[17] Dobutamine increases cardiac output and has limited effects 
on systemic pressure.[17] Norepinephrine is effective in improving 
oxygenation and improving systemic BP, and in newborn lambs 
was associated with improved postnatal adaptation and significantly 
decreased oxygen requirement.[17] Vasopressin and hydrocortisone 
may also be considered.[17]
Pulmonary vasodilators
Inhaled NO 
iNO is a potent and selective pulmonary vasodilator that leads to 
improved oxygenation and reduced need for ECMO by stimulating 
sGC activity to increase cGMP, a second messenger in the vasodilation 
pathway.[4,8,15] The use of iNO was FDA approved in 1999 for term 
and near-term infants with PPHN, especially when the OI is greater 
than 25.[3,6] The Neonatal Inhaled Nitric Oxide Study (NINOS) 
determined that the most effective starting dose of iNO is 20 ppm, 
and response should be seen within 30 - 60 minutes with an increase 
in PaO2 of 53 mmHg (8.6 kPa) or a decrease in OI of 15.[4,5,18,19] The 
use of iNO has significantly reduced the mortality of PPHN; however, 
~40% of patients will not respond to iNO.[2,6,10] Failure to respond to 
20 ppm is rarely followed by a response at a higher dosage.[8,18] The 
American Academy of Pediatrics (AAP) recommends the use of 
ECMO in non-responders.[20] Methaemoglobinaemia and increased 
nitrogen dioxide are known side-effects that occur more frequently 
at dosages greater than 20 ppm.[3,4] In patients with CDH, iNO can 
be attempted early with optimal ventilation and recruitment, but 
should be discontinued if no improvements are seen.[21]
iNO requires gradual weaning to avoid rebound PH (Table 6). The 
rebound phenomenon may appear even in patients who did not show 
any improvement on iNO initially.
In patients with PPHN refractory to iNO, ensure adequate lung 
recruitment, repeat echocardiogram and consider alternative 
treatments.[2]
Sildenafil
Sildenafil is a PDE5 inhibitor, which results in increased availability 
of cGMP, and subsequent selective reduction in PVR.[3-5,8,22] Increased 
PDE5 activity was documented in animal models with PPHN.[2] 
Enteral sildenafil, dose range 1 - 3 mg/kg every 6 hours, reduced 
mortality in resource-limited settings where iNO is not available 
and reduced rebound PH after the withdrawal of iNO.[4-6,13,22-24] A 
Cochrane review recommended this as a significant alternative for 
PPHN treatment when iNO is not available.[25] 
Table 5. Classification of PPHN severity[3]
Severity OI*†
Mild ≤15
Moderate >15 - 25
Severe 25 - 40
Very severe >40
OI = oxygenation index; MAP = mean airway pressure in cmH2O; FiO2 = fraction 
of inspired oxygen; PaO2 = partial pressure of oxygen in mmHg; OSI = oxygenation 
saturation index.
*OI = MAP × FiO2 × 100/PaO2.
†OI = OSI × 2; OSI = MAP × FiO2 × 100/pre-ductal saturation (no intravenous 
access required).
Table 6. Recommendations for use of iNO[3,4,6]




PaO2 >60 mmHg (>8 kPa)
Preductal saturation >90%
Above maintained for >60 minutes
Weaning 
procedure
Wean by 5 ppm every 2 - 4 hours till 5 ppm is reached





ppm = parts per million. 
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In the treatment of PH secondary to BPD, 
sildenafil at doses of 0.5 mg/kg every 8 hours 
to 2 mg/kg every 6 hours is considered safe 
and effective, and contributes to improved 
survival at 12 months.[23,26] 
Milrinone
Milrinone is a PDE3 inhibitor that leads 
to increased availability of cAMP, with 
resultant positive inotropic effects, peripheral 
vasodilatation, left ventricular afterload 
reduction and increased myocardial contract-
ility.[3,5,8,23] There are case reports of improved 
oxygenation in cases of PPHN refractory 
to iNO,[3,23] but there are also reports of an 
increased incidence of intracranial hae-
morrhages.[27]  Safety and efficacy is unknown, 
and therefore it is recommended for use only 
within randomised controlled trials (RCTs).[28]
Other drug therapies
Other promising treatment modalities in-
clude PGI2, magnesium sulphate, bosentan, 
adenosine, steroids and apocynin, but there 
is insufficient evidence to recommend any 
for routine or combination use (Table 7). 
Extracorporeal membrane 
oxygenation 
Although ECMO is viewed as the 
ultimate rescue therapy in developed 
countries, it is not freely available in low-
resource countries, therefore rendering 
its usefulness in developing countries 
questionable.[3,6] 
Special categories
Special consideration should be given when 
treating a patient with PPHN and perinatal 
asphyxia, as the treatment of PPHN may 
affect cerebral blood flow.[3,32] Inhaled NO 
does not significantly alter neurodevelop-
mental outcome.[3,32] The effects of 
moderate therapeutic hypothermia at 
33.5oC for 72 hours does not result in a 
significant increase in PPHN.[3] There 
are case reports that preceding hypoxia 
requiring FiO2  >50% and/or iNO may be 
associated with exacerbation of PPHN with 
hypothermia and/or rewarming.[3] Fluid 
boluses are not recommended in these 
patients, unless there is hypovolaemia, as it 
may increase cerebral oedema.[3,32] 
Outcome
The long-term neurological outcome is 
largely determined by the underlying 
condition. Neurodevelopmental impairment 
has been reported in up to 25% at 2 years of 
age and hearing impairment in 23%.[3,5]
At school age, there were 24% persistent 
respiratory problems, 60% abnormal chest 
X-rays, 6% sensorineural hearing loss, 9% IQ 
<90, and 7% IQ 70 - 84.[3] These infants require 
long-term multidisciplinary follow-up. 
Conclusion
PPHN is an acute neonatal disorder with 
complex underlying pathophysiology, which 
has a high mortality rate despite several 
advances in the management thereof. 
Inhaled NO is a safe and effective clinical 
strategy in the majority of patients, but is not 
always available in resource-limited settings. 
Oral sildenafil is a relatively safe alternative 
option in these settings. Newer drugs need to 
be studied before any recommendations can 
be made for routine use.
References
1. Gersony WM, Duc GV, Sinclair JC. “PFC” 
syndrome (persistence of fetal circulation). 
Circulation 1969;40(suppl 1):3-87.
2. Distefano G, Sciacca P. Molecular 
physiopathogenetic mechanisms and 
development of new potential therapeutic 
strategies in persistent pulmonary hypertension 
of the newborn. Ital J Pediatr 2015;41(1):6. http://
dx.doi.org/10.1186/s13052-015-0111-0
3. Sharma V, Berkelhamer S, Lakshminrusimha 
S. Persistent pulmonary hypertension of the 
newborn. Matern Health Neonatol Perinatol 
2015;1:14. http://dx.doi.org/10.1186/s40748-015-
0015-4
4. Puthiyachirakkal M, Mhanna MJ. 
Pathophysiology, management, and outcome of 
persistent pulmonary hypertension of the newborn: 
A clinical review. Front Pediatr 2013;1:23. http://
dx.doi.org/10.3389/fped.2013.00023 
5. Bendapudi P, Rao GG, Greenough A. Diagnosis 
and management of persistent pulmonary 
hypertension of the newborn. Paediatr Respir Rev 
2015;16(3):157-161. http://dx.doi.org/10.1016/j.
prrv.2015.02.001
6. Nair J, Lakshminrusimha S. Update on PPHN: 
Mechanisms and treatment. Semin Perinatol 
2014;38(2):78-91. http://dx.doi.org/10.1053/j.
semperi.2013.11.004
7. Jain A, McNamara PJ. Persistent pulmonary 
hypertension of the newborn: Advances in 
diagnosis and treatment. Semin Fetal Neonatal 
Med 2015:20(4):262-271. http://dx.doi.
org/10.1016/j.siny.2015.03.001 
8. Porta NFM, Steinhorn RH. Pulmonary vasodilator 
therapy in the NICU: Inhaled nitric oxide, 
sildenafil, and other pulmonary vasodilating 
agents. Clin Perinatol 2012;39(1):149-164. http://
dx.doi.org/10.1016/j.clp.2011.12.006 
9. Aggarwal S, Natarajan G. Echocardiographic 
correlates of persistent pulmonary 
hypertension of the newborn. Early Hum Dev 
2015;91(4):285-289. http://dx.doi.org/10.1016/j.
earlhumdev.2015.02.008 
10. Bendapudi P, Barr S. Diagnosis and management 
of pulmonary hypertension of the newborn. 
Paediatr Child Health 2014;24(1):12-16. http://
dx.doi.org/10.1016/j.paed.2013.05.021 
11. Hillman NH, Kallapur SG, Jobe AH. Physiology 
of transition from intrauterine to extrauterine life. 
Clin Perinatol 2012;39(4):769-783. http://dx.doi.
org/10.1016/j.clp.2012.09.009








Cannot be recommended for 
routine use




Bosentan[3-5,23] Non-selective endothelin 
receptor antagonist




Selective ETA receptor 
antagonists
More studies needed
Furegulate sodium[5] Thromboxane synthase 
inhibitor
34% reduction in PVR
Animal studies only
Adenosine[2,5] eNOS agonist Case series only




Postnatal systemic steroids[3,6,23] Reduced hospital stay and 
oxygen dependence in MAS
Not routinely recommended
More research needed, 
especially in limited-resource 
settings






Recombinant human SOD[6] - Animal studies only




PAP = pulmonary artery pressure; ETA = endothelin-A; ROS = reactive oxygen species; SOD = superoxide dismutase; 
NADPH = nicotinamide adenine dinucleotide phosphate.
*Case reports of improved oxygenation when stress doses used for systemic hypotension.
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